BHVN - Biohaven Pharmaceutical Holding Company Ltd.

NYSE - NYSE Delayed Price. Currency in USD
51.08
+2.06 (+4.20%)
At close: 4:02PM EST
Stock chart is not supported by your current browser
Previous Close49.02
Open49.52
Bid51.19 x 900
Ask51.26 x 800
Day's Range48.96 - 51.50
52 Week Range29.17 - 67.86
Volume881,221
Avg. Volume613,220
Market Cap2.668B
Beta (3Y Monthly)0.34
PE Ratio (TTM)N/A
EPS (TTM)-9.52
Earnings DateNov 1, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est76.25
  • Biohaven Readies for ‘David Versus Goliath’ Battle with Allergan
    Bloomberg

    Biohaven Readies for ‘David Versus Goliath’ Battle with Allergan

    (Bloomberg) -- Biohaven Pharmaceutical Holding Co. is readying for what Chief Executive Officer Vlad Coric calls a “David versus Goliath” showdown with large-cap competitor Allergan Plc in a race to sell a new class of migraine medicines.A potential first-quarter approval of Biohaven’s rimegepant, a medicine that has shown clinical success in treating migraines, would place it behind competitor Allergan’s expected approval next month. However, publications in the New England Journal of Medicine and the Lancet medical journals paired with plans to use direct-to-consumer advertising may give Biohaven a leg up, Coric said.“Telemedicine, e-commerce, social media; we’re going to incorporate a modern day launch with a traditional launch as well,” Coric said in an interview at Bloomberg’s New York headquarters on Tuesday. “If you’re prepared to run your business -- that will also open up a lot of optionality,” Coric added, when asked about plans for potential partnerships or deals to better compete with larger peers.Coric said a potential partnership or deal would have to be more than an “incremental” step as the company looks to “build value year-over-year,” he said.Biohaven -- long the subject of deal speculation, including a Bloomberg report in April that the company was exploring a sale -- has continued to build out a commercial team for the migraine drug. The New Haven, Connecticut-based company elected to raise roughly $300 million in a June public share offering to help bolster its cash reserves as it makes the jump from development to commercialization.Upcoming results from a migraine prevention study of rimegepant could also position the company better to compete with Allergan as the maker of Botox gets closer to completing its sale to AbbVie Inc., according to Coric. If the results are positive in the coming months, “that would give patients one dose of one drug” to help both treat and prevent migraine attacks, he said.Coric wants investors who may be focused solely on the regulatory decision for the company’s migraine drug to know that Biohaven will have data from other later-stage assets in the coming months. If successful, results from troriluzole in Alzheimer’s disease and generalized anxiety disorder may offer the drugmaker an opportunity to “transform,” he said.To contact the reporter on this story: Bailey Lipschultz in New York at blipschultz@bloomberg.netTo contact the editors responsible for this story: Catherine Larkin at clarkin4@bloomberg.net, Cristin Flanagan, Jeremy R. CookeFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • PR Newswire

    Kleo Pharmaceuticals Presents Preclinical Data Supporting Development of its CD38-ARM™, a Novel Immuno-therapeutic, at American Society of Hematology (ASH) Annual Meeting

    Company's Antibody Recruiting Molecules (ARMs) Demonstrated Strong Anti-Multiple Myeloma Activity In Multiple In Vivo Animal Models and Ex Vivo Against Patient Tumor Cells NEW HAVEN, Conn. , Nov. 6, 2019 ...

  • Biohaven Completes Enrollment In Pivotal Phase 2/3 Alzheimer's Disease Clinical Trial Of Troriluzole
    PR Newswire

    Biohaven Completes Enrollment In Pivotal Phase 2/3 Alzheimer's Disease Clinical Trial Of Troriluzole

    NEW HAVEN, Conn., Nov. 5, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, today announced that it has completed enrollment in the T2 Protect AD Study, a Phase 2/3 clinical trial of troriluzole in Alzheimer's disease. "We are hopeful this study will demonstrate that troriluzole can ameliorate the symptoms of Alzheimer's disease, by reducing synaptic glutamate through a novel mechanism of action," said Howard Feldman, MD, FRCP(C), Director of the Alzheimer's Disease Cooperative Study (ADCS) and Professor of Neurosciences at the University of California San Diego School of Medicine, who is Principal Investigator of the T2 Protect AD Study.

  • Biohaven Statement Regarding Kleo Pharmaceuticals (Kleo): Thomas J. Lynch, Jr., MD, Appointed As Kleo Chairman Of The Board
    PR Newswire

    Biohaven Statement Regarding Kleo Pharmaceuticals (Kleo): Thomas J. Lynch, Jr., MD, Appointed As Kleo Chairman Of The Board

    - Biohaven was a founding investor and the company's current ownership interest in outstanding stock of Kleo is 41.9%. NEW HAVEN, Conn., Nov. 4, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) a clinical-stage biopharmaceutical company provided an update regarding the appointment of Thomas J. Lynch, Jr., MD, as Chairman of the Board at Kleo Pharmaceuticals.

  • Biohaven Pharmaceuticals Reports Third Quarter 2019 Financial Results And Recent Business Developments
    PR Newswire

    Biohaven Pharmaceuticals Reports Third Quarter 2019 Financial Results And Recent Business Developments

    - Announced acceptance by the United States Food and Drug Administration (FDA) of the new drug applications (NDAs) for rimegepant and expected Prescription Drug User Fee Act (PDUFA) date of the first quarter ...

  • Biohaven Completes Enrollment In Phase 3 Generalized Anxiety Disorder (GAD) Trial Of Troriluzole
    PR Newswire

    Biohaven Completes Enrollment In Phase 3 Generalized Anxiety Disorder (GAD) Trial Of Troriluzole

    NEW HAVEN, Conn., Oct. 28, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurologic and neuropsychiatric diseases, today announced that it has completed enrollment in its pivotal Phase 3 clinical trial assessing the efficacy and safety of troriluzole in generalized anxiety disorder (GAD). GAD is a chronic and long-lasting disorder in which a person has uncontrollable, excessive anxiety and worry and is often associated with significant functional impairment. According to the Anxiety and Depression Association of America (ADAA), millions of Americans suffer from GAD.  If not appropriately treated, GAD has a chronic course associated with significant disability and high public burden.

  • Hedge Funds Have Never Been This Bullish On Biohaven Pharmaceutical Holding Company Ltd. (BHVN)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Biohaven Pharmaceutical Holding Company Ltd. (BHVN)

    World-class money managers like Ken Griffin and Barry Rosenstein only invest their wealthy clients' money after undertaking a rigorous examination of any potential stock. They are particularly successful in this regard when it comes to small-cap stocks, which their peerless research gives them a big information advantage on when it comes to judging their worth. […]

  • Biohaven's Verdiperstat, An Oral Myeloperoxidase Inhibitor, Selected For Platform Trial Collaboration At Massachusetts General Hospital's Healey & AMG Center For Amyotrophic Lateral Sclerosis (ALS)
    PR Newswire

    Biohaven's Verdiperstat, An Oral Myeloperoxidase Inhibitor, Selected For Platform Trial Collaboration At Massachusetts General Hospital's Healey & AMG Center For Amyotrophic Lateral Sclerosis (ALS)

    NEW HAVEN, Conn., Sept. 18, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) ("Biohaven" or the "Company"), a clinical stage biopharmaceutical company with a portfolio of late-stage product candidates for neurological and neuropsychiatric diseases, announced today that the Company's myeloperoxidase (MPO) inhibitor, verdiperstat, has been selected as an investigational therapy in the first Amyotrophic Lateral Sclerosis (ALS) platform trial, an innovative program designed by the Sean M. Healey & AMG Center for ALS at Mass General to help accelerate a path to new and effective ALS treatments. Verdiperstat is a potential first-in-class, oral, brain-penetrant, irreversible inhibitor of the MPO enzyme.

  • Biohaven Advances NOJECTION™ Migraine Platform With Completion Of Enrollment Of Pivotal Phase 2/3 Trial Of Vazegepant, The First Intranasally Administered CGRP Receptor Antagonist In Development For The Acute Treatment Of Migraine
    PR Newswire

    Biohaven Advances NOJECTION™ Migraine Platform With Completion Of Enrollment Of Pivotal Phase 2/3 Trial Of Vazegepant, The First Intranasally Administered CGRP Receptor Antagonist In Development For The Acute Treatment Of Migraine

    NEW HAVEN, Conn., Sept. 10, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN), a biotechnology company focused on advancing innovative therapies for neurological and neuropsychiatric diseases, today announced completion of enrollment in its Phase 2/3, double-blind, randomized, placebo-controlled, dose-ranging trial of intranasally administered vazegepant (formerly BHV-3500) for the acute treatment of migraine. Vazegepant is a novel, structurally unique, third-generation calcitonin gene-related peptide (CGRP) receptor antagonist and the second product candidate in development for the acute treatment of migraine from Biohaven's NOJECTION™ Migraine Platform.

  • Biohaven Presents Data Demonstrating Reduction In Migraine-Related Disability And Improvement In Patient Reported Outcomes After Oral Treatment With Rimegepant At The International Headache Conference Late Breaking Session
    PR Newswire

    Biohaven Presents Data Demonstrating Reduction In Migraine-Related Disability And Improvement In Patient Reported Outcomes After Oral Treatment With Rimegepant At The International Headache Conference Late Breaking Session

    · Acute treatment of migraine with rimegepant, an oral CGRP-antagonist, decreased disability by approximately 41% as measured by the Migraine Disability Assessment (MIDAS) · Rimegepant treatment also demonstrated ...

  • Biohaven Pharmaceuticals Reports Second Quarter 2019 Financial Results and Recent Business Developments
    PR Newswire

    Biohaven Pharmaceuticals Reports Second Quarter 2019 Financial Results and Recent Business Developments

    NEW HAVEN, Conn., Aug. 8, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN, the "Company"), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, today reported financial results for the quarter ended June 30, 2019, and provided a review of recent accomplishments and anticipated milestones.

  • Biohaven Completes Enrollment In Pivotal Phase 3 Migraine Prevention Trial
    PR Newswire

    Biohaven Completes Enrollment In Pivotal Phase 3 Migraine Prevention Trial

    NEW HAVEN, Conn., Aug. 7, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases today reported completion of enrollment in its pivotal Phase 3 preventive treatment of migraine trial with rimegepant, its lead oral calcitonin gene-related peptide (CGRP) receptor antagonist product candidate.

  • Biohaven Enrolls First Patient In Phase 3 Clinical Trial Of Verdiperstat, Oral Myeloperoxidase Inhibitor, For The Treatment Of Multiple System Atrophy
    PR Newswire

    Biohaven Enrolls First Patient In Phase 3 Clinical Trial Of Verdiperstat, Oral Myeloperoxidase Inhibitor, For The Treatment Of Multiple System Atrophy

    NEW HAVEN, Conn., July 31, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) ("Biohaven" or the "Company"), a clinical stage biopharmaceutical company with a portfolio of late-stage product candidates for neurological and neuropsychiatric diseases, announced today that it enrolled the first patient in a Phase 3 clinical trial to evaluate the efficacy and safety of verdiperstat in subjects with Multiple System Atrophy ("MSA"). Results from a previous Phase 2 trial in MSA completed by AstraZeneca AB showed evidence of target engagement and favorable trends over 12 weeks on the Unified MSA Rating Scale, an exploratory clinical outcome measure. Verdiperstat has received orphan drug designation for the treatment of MSA from the FDA Office of Orphan Products Development as well as the European Commission upon recommendation from the European Medicines Agency's Committee for Orphan Medicinal Products.

  • Release Your 'Inner Spock' When Investing in Biotech Stocks
    TheStreet.com

    Release Your 'Inner Spock' When Investing in Biotech Stocks

    The speed, and in a lot of cases overreaction, to news events has just become worse over the years thanks to the advent of 24/7 trading, the huge amount of information available to the average investor and algorithmic or program trading. For those logical and rational biotech investors out there, these sorts of fast-moving opportunities come along quite frequently and can nicely enhance your portfolio returns.

  • Biohaven Provides Update On Phase 2/3 Alzheimer's Disease Clinical Trial: Over 400 Patients Enrolled
    PR Newswire

    Biohaven Provides Update On Phase 2/3 Alzheimer's Disease Clinical Trial: Over 400 Patients Enrolled

    NEW HAVEN, Conn., July 22, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, today announced that enrollment in the T2 Protect AD Study, a Phase 2/3 clinical trial of troriluzole in Alzheimer's disease, is progressing on timelines with more than 400 subjects enrolled (for screening) and over 180 subjects randomized to study treatment (troriluzole or placebo). The T2 Protect AD Study (clinicaltrials.gov identifier NCT03605667) is a Phase 2/3, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of troriluzole in patients diagnosed with Alzheimer's disease of mild-to-moderate severity (Mini-Mental State Examination scores of 14-24).

  • Biohaven's Nurtec (riluzole) 505(b)2 Application for Amyotrophic Lateral Sclerosis Affected by Issues Related to Apotex Plant: Complete Response Letter (CRL) Received From FDA Related to Isolated Drug Substance Supply Used in Bioequivalence Study
    PR Newswire

    Biohaven's Nurtec (riluzole) 505(b)2 Application for Amyotrophic Lateral Sclerosis Affected by Issues Related to Apotex Plant: Complete Response Letter (CRL) Received From FDA Related to Isolated Drug Substance Supply Used in Bioequivalence Study

    - Biohaven is already engaged with the FDA regarding next steps for a timely resolution of this matter and has submitted additional information to the Agency. -FDA cited issues with the active pharmaceutical ingredient (API) used in the Biohaven 2017 bioequivalence study that was manufactured between 2014 and 2016 in an Apotex facility. -Biohaven notes that the API for its commercial supply of Nurtec is sourced from another supplier, with whom there are no current issues.

  • Biohaven's Positive Phase 3 Trial of Rimegepant Zydis® Orally Dissolving Tablet for Acute Treatment of Migraine Published in The Lancet
    PR Newswire

    Biohaven's Positive Phase 3 Trial of Rimegepant Zydis® Orally Dissolving Tablet for Acute Treatment of Migraine Published in The Lancet

    NEW HAVEN, Conn., July 15, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) announces that The Lancet published online positive results from a Phase 3 pivotal clinical trial of rimegepant Zydis® orally dissolving tablet (ODT) for the acute treatment of migraine.

  • Biohaven Launches 'Demand More' Campaign At 2019 American Headache Society Annual Scientific Meeting: Highlighting Patient Needs In Acute Treatment Of Migraine
    PR Newswire

    Biohaven Launches 'Demand More' Campaign At 2019 American Headache Society Annual Scientific Meeting: Highlighting Patient Needs In Acute Treatment Of Migraine

    -Research suggests patients define effective migraine therapies as reliable pain relief that enables them to return to their lives. Current treatments limit the ability for some patients to reach their treatment goals due to nonresponse to standard therapies and side effects. NEW HAVEN, Conn., July 11, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN), has launched a campaign called 'Demand More' highlighting what patients want and need from an acute treatment of migraine in their own words.

  • Biohaven Showcases Positive Data on Rimegepant, Oral CGRP Receptor Antagonist, with 16 Presentations at 2019 American Headache Society (AHS) Annual Scientific Meeting Demonstrating Efficacy in Multiple Patient Types and Long-term Safety
    PR Newswire

    Biohaven Showcases Positive Data on Rimegepant, Oral CGRP Receptor Antagonist, with 16 Presentations at 2019 American Headache Society (AHS) Annual Scientific Meeting Demonstrating Efficacy in Multiple Patient Types and Long-term Safety

    - Rimegepant Zydis® Oral Fast-Dissolve Tablet (ODT) Phase 3 results demonstrate rapid and sustained benefits for the acute treatment of migraine - Presentations also include: -New interim analyses from ...

  • Benzinga

    The Daily Biotech Pulse: Neurocrine's Parkinson's Drug Accepted For Review, Sunesis Offering, No Headaches For Biohaven's Migraine Drug

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 10) CONMED Corporation (NASDAQ: CNMD ) Eidos Therapeutics ...

  • Biohaven's Rimegepant Positive Phase 3 Trial For Acute Treatment Of Migraine Published In The New England Journal of Medicine
    PR Newswire

    Biohaven's Rimegepant Positive Phase 3 Trial For Acute Treatment Of Migraine Published In The New England Journal of Medicine

    NEW HAVEN, Conn., July 10, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN), announced today that positive results from a Phase 3 pivotal clinical trial of rimegepant, Biohaven's small molecule calcitonin gene-related peptide (CGRP) receptor antagonist, for the acute treatment of migraine, are published in the July 12, 2019 issue of the New England Journal of Medicine (NEJM).

  • 2 Single Hitters That Could Score With the 'Write' Strategy
    TheStreet.com

    2 Single Hitters That Could Score With the 'Write' Strategy

    The contest was won by rookie Peter Alonso -- about the only good thing about the Mets season to this point. The stock fell some 30% in short order after announcing and executing a $300 million secondary offering to raise funding.

  • GuruFocus.com

    Biohaven Offering Seems to Make Sale Less Likely

    Company among 4 small cap pharma firms listed as takeover targets

  • Biohaven reveals positive results in migrane drug trial
    Yahoo Finance Video

    Biohaven reveals positive results in migrane drug trial

    Biohaven Pharmaceuticals, which recently announced a positive Stage 3 trial for one of its migraine treatments. Dr. Vlad Coric, CEO of Biohaven, discusses the future of the drug and the company with Yahoo Finance's Alexis Christoforous and Brian Sozzi